Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | The potential of differentiation therapies for AML

Stéphane de Botton • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Enasidenib

Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses the efficiency of differentiation therapies for the elimination of acute myeloid leukemia at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH). Dr de Botton emphasizes the need to further improve results via the use of combination therapies, and describes how enasidenib can be combined with a wide variety of targeted drugs and other agents.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Stéphane de Botton

The challenges of predicting and diagnosing differentiation syndrome
2:24
The challenges of predicting and diagnosing differentiation syndrome
Stéphane de Botton • 19 Sep 2026
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML
9:36
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML
Stéphane de Botton • 18 Sep 2026
Optimal dose, duration and de-escalation of venetoclax in AML
7:12
Optimal dose, duration and de-escalation of venetoclax in AML
Stéphane de Botton • 19 Sep 2026
Current evidence base for de-escalating venetoclax in AML
1:00
Current evidence base for de-escalating venetoclax in AML
Stéphane de Botton • 18 Sep 2026

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals